Alterity Therapeutics Ltd. has released a press release.
$4.2M Options Underwriting Agreement Executed
Earlier from Alterity Therapeutics
- Appendix 4E and 2026 Annual Report
- Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
- Granted New U.S. Composition of Matter Patent for ATH434
- Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update